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Concurrent chemoradiotherapy is standard treatment for anal cancer. Following national UK 3 
implementation of intensity-modulated radiotherapy (IMRT) this prospective, national 4 
cohort evaluates the 1-year oncological outcomes and patient-reported toxicity outcomes 5 
(PRO) after treatment. 6 
Materials and Methods 7 
A national cohort of UK cancer centres implementing IMRT was carried out between 8 
February to July 2015. Cancer centres provided data on oncological outcomes including 9 
survival, and disease and colostomy status at 1-year. EORTC-QLQ core (C30) and colorectal 10 
(CR29) questionnaires were completed at baseline and 1-year follow-up. The PRO scores at 11 
baseline and 1-year were compared.  12 
Results 13 
40 UK Cancer Centres returned data with a total of 187 patients included in the analysis. 14 
92% received mitomycin with 5-flurouracil or capecitabine. 1-year overall survival was 94%; 15 
84% were disease-free and 86% colostomy-free at 1-year follow up. At 1-year, PRO results 16 
found significant improvements in buttock pain, blood and mucous in stools, pain, 17 
constipation, appetite loss, and health anxiety compared to baseline. No significant 18 
deteriorations were reported in diarrhoea, bowel frequency, and flatulence. Urinary 19 
symptom scores were low at 1-year. Moderate impotence symptoms at baseline remained 20 
at 1-year and a moderate deterioration in dyspareunia reported. 21 
 3 
Conclusions 1 
With national anal cancer IMRT implementation, at this early pre-defined time point, 1-year 2 
oncological outcomes were reassuring and result in good disease-related symptom control. 3 
1-year symptomatic complications following CRT for anal cancer using IMRT techniques 4 
appear to be relatively mild. These PRO results provide a basis to benchmark future studies.  5 
  6 
Introduction 7 
Concurrent chemoradiotherapy is the standard of care for anal cancer treatment[1, 2]. In 8 
2012, the UK department of health recommended implementation of intensity modulated 9 
radiotherapy (IMRT) (including volumetric modulated arc therapy (VMAT) and tomotherapy) 10 
with the aim of reducing toxicity from radiotherapy through sculpting of the beams and 11 
dose[3]. Within clinical trials, radiotherapy protocol deviations are known to impact on 12 
treatment failure and oncological outcomes[4]. Therefore, to optimise implementation of 13 
IMRT in a rare cancer, the Royal College of Radiologists supported the development of a 14 
national protocol and implementation strategy[5]. This national cohort was carried out with 15 
the aim of collecting prospective data to investigate IMRT delivery[6], to assess early 16 
toxicity[7], oncological outcomes and health-related quality of life (HRQOL). 17 
 18 
A small number of studies in anal cancer, including prospective phase II trials, have reported 19 
on improved disease outcomes and treatment-related acute toxicity with the introduction 20 
of IMRT techniques[8-11]. Cross-sectional studies using patient-reported outcomes (PROs) 21 
have found patients report long-term toxicity related to bowel, urinary and sexual 22 
dysfunction post-treatment[12, 13]. However, there is a lack of prospectively collected PROs 23 
 4 
measuring toxicity and HRQOL following anal cancer chemoradiotherapy from both IMRT 1 
and conformal techniques[13]. Baseline PRO data is important to be able to establish the 2 
true symptomatic benefit of treatment and to distinguish between toxicity and pre-morbid 3 
symptoms. In addition, there is also a lack of data outside of single-centre series. This paper 4 
presents the prospective evaluation of the impact of IMRT on patient-reported toxicity 5 
including HRQOL at 1-year in a national anal cancer cohort supplemented with oncological 6 
outcomes.  7 
 8 
Materials and Methods 9 
Prospective data collection from all UK National Health Service (NHS) cancer centres (n=56) 10 
in patients with a diagnosis of anal cancer starting IMRT over a 6-month period from 9 11 
February to 27 July 2015 was requested. Full details are reported elsewhere[6]. Data 12 
collection was performed by the RCR as part of a national prospective cohort program in 13 
which approval was obtained by each NHS institution's research and governance board with 14 
a pre-planned 1-year follow-up schedule.  15 
 16 
Patient demographic data at baseline included age, gender, stoma status, HIV and smoking 17 
status. Tumour and treatment information included TNM staging, radiotherapy dose and 18 
fractionation and concurrent chemotherapy schedule. Acute toxicity data was collected 19 
weekly during treatment using CTCAEv4[14] and reported grade 3/4 toxicity in any category 20 
used in the analysis. Full details of demographics and acute toxicity have been reported 21 
previously[6].  22 
 23 
 5 
Patients were invited to complete the validated European Organisation for Research and 1 
Treatment of Cancer QOL questionnaires (EORTC-QLQ) core module (C30) and colorectal 2 
cancer module (CR29)[15, 16]. An anal cancer-specific module was not available at the time 3 
of recruitment[17]. The C30 is a generic questionnaire including items on overall HRQOL, 4 
physical, role, social, emotional and cognitive function as well as generic symptoms affecting 5 
cancer patients including fatigue, diarrhoea and pain. CR29 addresses disease-specific 6 
concerns including bowel, urinary and sexual symptoms.  7 
 8 
PRO collection was coordinated by clinical teams at each cancer centre and patients were 9 
invited to complete paper questionnaires at two timepoints – baseline (prior to or on day 1 10 
of starting radiotherapy) and at 1-year. Invitations to report 1-year follow up data were sent 11 
between 14 July 2016 and 18 November 2016 via three email reminders to clinical teams 12 
(Range 353-648days). Paper questionnaires were either handed out at clinic appointments 13 
for completion or sent to patients in the post with a return (stamped) envelope at the 14 
discretion of the clinical team. Resources for this national program were restricted. 15 
 16 
Descriptive and regression analyses were performed using Stata v13.1[18]. Descriptive 17 
statistics were used to describe patient, clinical and tumour characteristics. Descriptive 18 
analysis was performed on 1-year oncological outcomes as event rates were too low to 19 
carry out more extensive analyses.  Disease-free status was defined as disease that had 20 
achieved a complete response and not demonstrated recurrence[19] and missing data 21 
explored using logistic regression.    22 
 23 
 6 
Exploratory analyses of EORTC QLQs and handling of missing data were performed 1 
according to EORTC guidelines, using a process of imputing missing values in scaled 2 
responses[20]. All item responses from the PROs were converted from a four-point Likert-3 
type scale through a linear transformation onto a 0-100 scale. Higher scores for symptom 4 
items reflect more severe symptoms (i.e. ‘not at all’=0; ‘a little’=33.3; ‘quite a bit’=66.6; 5 
‘very much’=100); higher scores for function items reflect a better level of functioning[20]. A 6 
minimum important difference (MID) was classified as a small change in scores from 5 to 10 7 
points, moderate differences as a change up to 20 points and large differences as a change 8 
in scores of >20[21].  9 
 10 
Mean and paired differences between baseline PRO scores and 1-year follow-up were 11 
evaluated. A two-sided t-test was used to evaluate statistical significance with a p-value 12 
<0.01 deemed to be significant, after Bonferroni correction for multiple comparisons. 13 
Multivariable linear regression analysis was performed to evaluate the impact of age, 14 
gender, acute (any) grade 3/4 toxicity, tumour stage and nodal stage on PRO items (p<0.01). 15 
Reasons for missing PRO data at baseline and 1-year follow up were explored using 16 
multivariable logistic regression, including age, gender, disease status, cancer centre, T 17 
stage and baseline PRO completion rates as confounders. An exploratory analysis compared 18 
mean PRO scores (for pre-defined PRO items taken from CORMAC core outcome set) at 19 
baseline and 1-year by risk groups; early stage T1/2N0 versus locally advanced T3/4 and/or 20 
N+[19, 22].  21 
 7 
Results 1 
Patient characteristics 2 
1-year follow up data was collected in 40 UK Cancer Centres (71%), with numbers of 3 
participants included from each centre ranging from 1-13 participants (Median 4 per 4 
centre). Patient and tumour characteristics are summarised in Table 1 and 2 respectively. All 5 
187 patients who received radical (curative intent) IMRT were included in this analysis, 6 
including patients who received full dose IMRT adherent to UK guidance (n=157)[6], those 7 
who received full dose IMRT not strictly adherent to UK guidance (n=23) and those receiving 8 
reduced dose IMRT (n=7) (see supplementary figure).  Median radiotherapy dose received 9 
was 53.2Gy in 28 fractions(F) (Range 30-53.2Gy in 10-30F); T1/2 received median dose 10 
50.4Gy in 28F (Range 30-54Gy in 10-30F) and T3/4 received median dose 53.2Gy in 28F 11 
(Range 40-54Gy in 15-30F). The majority of patients (n=153) completed full dose 12 
chemotherapy (n=27 dose reduced/omitted secondary to toxicity; n=7 no chemotherapy 13 
given) (see [6] for more details). 14 
 15 
1-year survival data was available for 109 (58.2%) patients during follow-up. At 3-months no 16 
patients were known to have died. At 6-months 2 deaths were known to have occurred - 17 
both patients had residual local disease at 3-months. At 1-year, 6 patients in total had died - 18 
94% 1-year overall survival. All 6 patients had evidence of local or distant disease, with 4 19 
patients with residual local disease reported at 3-months. Disease-free survival status was 20 
available on 107 patients (57.2%) (2 patients were alive with unknown disease status). At 1-21 
year, 84 were disease-free (78.5%), and 13 had local disease failure reported (5 underwent 22 
salvage surgery; 5 local regional failure; 3 LRR and metastatic disease) (12.1%). Table 3 23 
 8 
presents 1-year oncological outcomes by patient, treatment and disease characteristics. The 1 
event rate (6 deaths) was too low to comment on any trends in the data. 86% of patients 2 
were colostomy-free at 1-year (n=97/113). In regards missing data, centres either returned 3 
oncological outcome data or did not return any.  4 
 5 
Exploratory PRO and HRQOL analysis 6 
A total of 121 (65%) of patients reported some PRO data at either time-point, with 115 7 
(61%) completing at least one PRO item at baseline and 57 (30%) at 1-year. 103 (55%) had 8 
complete data across all subscales at baseline and 54 (29%) at 1-year follow up. 43 (23%) of 9 
patients have complete subscale data at both time-points. No patient, clinical or tumour 10 
characteristics predicted missing PRO data. At baseline, only cancer centre appeared to 11 
predict missing questionnaires reflecting the administration approach to PRO data collection 12 
(p=0.02). At 1-year, there were no significant predictors of missing questionnaire data.  13 
 14 
Table 4 describes the PRO mean scores at baseline and 1-year follow-up and mean and 15 
paired differences. Pain, constipation, appetite loss, anxiety, blood and mucous in stools, 16 
and buttock pain were all significantly improved at 1-year (mean differences). On review of 17 
MID between scores at baseline and 1-year, only dyspareunia showed a moderate clinical 18 
deterioration in mean scores (14.5 to 29.5). Otherwise moderate improvements were noted 19 
for role and emotional functioning and symptom scores: pain, constipation, appetite loss, 20 
anxiety, blood and mucous in stools. A large improvement in buttock pain from baseline was 21 
reported.   22 
 23 
 9 
In terms of 1-year toxicity, it is reassuring that there was no clinically significant 1 
deteriorations reported with PRO items on diarrhoea, bowel frequency, flatulence, urinary 2 
frequency or impotence. Mean scores at 1-year for all bowel items ranged between 19.1 to 3 
38.8 correlating to a patient reporting a ‘mild’ symptom[23]. Stoma scores are not included 4 
due to low numbers of patients reporting (n=13 at baseline and n=6 at 1-year).  5 
 6 
The sample size for sexual toxicity items was small as only 34% of women reported on 7 
symptoms (n=46) and 50% of men (n=26). However, impotence scores for men remained 8 
relatively poor (mean score 46.6 – moderate symptoms) at 1-year but did not significantly 9 
deteriorate after treatment. For women, dyspareunia showed a moderate deterioration in 10 
mean scores but overall the 1-year mean score (29.4) relates to ‘mild’ symptoms. 11 
 12 
The items with the most severe symptom mean scores at 1-year were flatulence, 13 
impotence, libido (for both men and women), and health anxiety. Although, both health 14 
anxiety and female libido showed a moderate and small improvement, respectively, from 15 
baseline scores. All other changes were minor. In regards HRQOL and function, moderate 16 
improvements at 1-year were noted for role and emotional functioning. 17 
 18 
Regression analysis on predictors of significant PRO change between baseline and 1-year 19 
found change in pain scores was predicted by gender, with women reporting less of an 20 
improvement in pain scores over time (p=0.004); and acute G3/4 toxicity, with patients 21 
reporting a greater improvement in pain scores if they had reported any G3/4 toxicity 22 
during treatment or if this data was unknown as compared to patients with no G3/4 toxicity 23 
 10
(p=0.007). Similarly, change in buttock pain scores found women reporting less 1 
improvement in pain over time (p=0.01).  2 
 3 
The exploratory analysis by risk groups (supplementary file), found locally advanced 4 
tumours have poorer baseline scores but report relatively greater improvements in function 5 
and cancer symptoms. In comparison, patients with early stage tumours are less 6 
compromised by cancer-related issues at baseline but have a proportionally greater change 7 
in scores by 1-year representing more toxicity-related issues.  8 
  9 
Discussion 10 
To our knowledge this is the largest, multicentre prospective cohort of 1-year oncological 11 
outcomes including PRO assessment of anal cancer patients treated with curative intent 12 
IMRT. The results provide a comprehensive evaluation of patients treated in routine 13 
practice in the UK.  14 
 15 
The 1-year oncological outcomes found patients to have reassuringly high overall (94%), 16 
disease-free (84%) and colostomy-free (86%) survival in line other prospective studies of 17 
IMRT and randomised studies of conformal radiotherapy in anal cancer[2, 9, 24].  18 
 19 
The toxicity rates for all symptoms are generally low and improvements in disease-related 20 
symptoms, such as buttock pain and per rectal bleeding, significant. Importantly at 1-year, 21 
there were no significant deteriorations seen in bowel toxicity items including diarrhoea, 22 
bowel frequency, and flatulence, although flatulence symptom scores remained moderately 23 
 11
severe (40.2). Urinary symptoms also did not significantly deteriorate at 1-year, although 1 
studies of pelvic radiotherapy with longer follow up have found that whilst bowel symptoms 2 
may improve after 1-year, urinary symptoms may deteriorate over a longer timeframe[26]. 3 
Whilst the sample for patients reporting on sexual function is small, it is important to note 4 
that dyspareunia deteriorated moderately at 1-year; and impotence symptom scores 5 
remained moderately severe, with a relatively greater deterioration seen in earlier cancers.  6 
 7 
The 1-year PRO toxicity scores are similar to those reported in single-centre series of 8 
patients treated with IMRT[9, 27]. Although the use of different questionnaires and quality 9 
of reporting can make it challenging to directly compare results with other studies, the rates 10 
of late toxicity for bowel and erectile function using IMRT appear to be lower than cross-11 
sectional series of patients treated with conformal techniques[28-31]. These findings are 12 
likely to reflect the sculpted dose around bowel and penile bulb structures resulting in 13 
reduced dose anteriorly[32]. For example, within the current study at 1-year patients 14 
reported mild diarrhoea symptoms (mean 16.4; SD22.0). Similarly, contemporary studies of 15 
patients treated with IMRT report mild symptoms with mean scores ranging from 12-22.8[9, 16 
27]. In comparison, older studies have reported moderate diarrhoea symptom scores with 17 
mean scores between 27-34.6[28, 30, 31, 33]. Similarly, large to moderate improvements 18 
using IMRT are observed with symptoms of flatulence, faecal incontinence and 19 
impotence[27, 30, 31]. Our rates of dyspareunia, urinary frequency and incontinence were 20 
similar to results from previous conformal and IMRT studies. Vaginal doses remain high as 21 
the structure is directly adjacent to the high dose tumour volume, whilst bladder symptoms 22 
may be more reflective of pre-morbid symptoms as minimal change was observed from 23 
baseline[34, 35].  24 
 12
 1 
The exploratory analysis lends credence to the need to improve symptoms with a significant 2 
impact on QOL, such as flatulence, dyspareunia and impotence, and this should be a target 3 
for future studies de-escalating dose in patients with low-risk anal cancer[22]. Indeed, these 4 
data provide a benchmark to test improvements in PRO from reduced dose IMRT in early 5 
stage disease and to assess any potential ‘cost’ in PRO from efforts to improve locoregional 6 
control in advanced disease with increasing radiotherapy doses, as is being tested in the 7 
ongoing platform trial, PLATO (personalizing anal cancer radiotherapy dose; registry no. 8 
ISRCTN88455282)[22]. 9 
 10 
Due to the restricted resources available for national programs, there are missing data for 11 
both PRO and oncological outcomes, more so at 1-year follow-up. The event rate therefore 12 
could be underestimated although PRO scores and oncological event rates were similar to  13 
expected. This demonstrates the limitations of unfunded multi-centre national audit 14 
programs. However, it is reassuring than no patient, clinical or tumour characteristics 15 
appeared to predict missing data. Only centres failing to return data appears to be in effect, 16 
which provides a strong argument in support of the reliability of these results. The authors 17 
also acknowledge that 1-year is an early timepoint in follow-up. A further limitation is 18 
standardised quality assurance for IMRT implementation and delivery. At the time of patient 19 
recruitment, no validated anal cancer specific PRO existed and therefore as in other studies, 20 
the EORTC-QLQ CR29 was used for evaluation. Whilst this provides good quality data, a 21 
number of important long-term toxicity issues are missing; of particular note, symptoms 22 
related to bowel urgency, toilet dependency, and vaginal symptoms such as vaginal dryness 23 
and stenosis. These issues are present in the newly developed EORTC-QLQ ANL27, which is 24 
 13
currently under phase IV international validation testing and included in the PLATO trial[17, 1 
36]. Future studies should use the EORTC-QLQ ANL27 to provide an accurate understanding 2 
of patient disease and toxicity burden [37]  and prioritise a priori selection of key PRO items 3 
highlighted in CORMAC, the anal cancer core outcome set, for hypothesis testing[19].  4 
 5 
Conclusions 6 
In comparison to other studies reporting PRO and HRQOL in anal cancer, our study provides 7 
PRO data in a multicentre prospective setting. The effective implementation of IMRT in a 8 
national setting was reported previously[6]. At 1-year, early oncological outcomes were 9 
reassuring and result in good disease-related symptom control measured with PROs. In 10 
comparison to historical series of conformal radiotherapy, these results also suggest 11 
benefits in the reduction of bowel and male sexual dysfunction at 1-year. These findings, as 12 
well as providing prospective PRO toxicity data to better understand patient experience, 13 
may also provide the basis for benchmarking future studies.  14 
 15 
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